Cargando…

Untargeted serum metabolomics reveals potential biomarkers and metabolic pathways associated with esophageal cancer

Metabolomics has been reported as an efficient tool to screen biomarkers that are related to esophageal cancer. However, the metabolic biomarkers identifying malignant degrees and therapeutic efficacy are still largely unknown in the disease. Here, GC-MS-based metabolomics was used to understand met...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xiao-li, Wang, Peng, Ye, Hua, Jiang, Ming, Su, Yu-bin, Peng, Xuan-xian, Li, Hui, Zhang, Jian-ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513043/
https://www.ncbi.nlm.nih.gov/pubmed/36176418
http://dx.doi.org/10.3389/fonc.2022.938234
_version_ 1784797967088091136
author Yang, Xiao-li
Wang, Peng
Ye, Hua
Jiang, Ming
Su, Yu-bin
Peng, Xuan-xian
Li, Hui
Zhang, Jian-ying
author_facet Yang, Xiao-li
Wang, Peng
Ye, Hua
Jiang, Ming
Su, Yu-bin
Peng, Xuan-xian
Li, Hui
Zhang, Jian-ying
author_sort Yang, Xiao-li
collection PubMed
description Metabolomics has been reported as an efficient tool to screen biomarkers that are related to esophageal cancer. However, the metabolic biomarkers identifying malignant degrees and therapeutic efficacy are still largely unknown in the disease. Here, GC-MS-based metabolomics was used to understand metabolic alteration in 137 serum specimens from patients with esophageal cancer, which is approximately two- to fivefold as many plasma specimens as the previous reports. The elevated amino acid metabolism is in sharp contrast to the reduced carbohydrate as a characteristic feature of esophageal cancer. Comparative metabolomics showed that most metabolic differences were determined between the early stage (0–II) and the late stage (III and IV) among the 0–IV stages of esophageal cancer and between patients who received treatment and those who did not receive treatment. Glycine, serine, and threonine metabolism and glycine were identified as the potentially overlapped metabolic pathway and metabolite, respectively, in both disease progress and treatment effect. Glycine, fructose, ornithine, and threonine can be a potential array for the evaluation of disease prognosis and therapy in esophageal cancer. These results highlight the means of identifying previously unknown biomarkers related to esophageal cancer by a metabolomics approach.
format Online
Article
Text
id pubmed-9513043
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95130432022-09-28 Untargeted serum metabolomics reveals potential biomarkers and metabolic pathways associated with esophageal cancer Yang, Xiao-li Wang, Peng Ye, Hua Jiang, Ming Su, Yu-bin Peng, Xuan-xian Li, Hui Zhang, Jian-ying Front Oncol Oncology Metabolomics has been reported as an efficient tool to screen biomarkers that are related to esophageal cancer. However, the metabolic biomarkers identifying malignant degrees and therapeutic efficacy are still largely unknown in the disease. Here, GC-MS-based metabolomics was used to understand metabolic alteration in 137 serum specimens from patients with esophageal cancer, which is approximately two- to fivefold as many plasma specimens as the previous reports. The elevated amino acid metabolism is in sharp contrast to the reduced carbohydrate as a characteristic feature of esophageal cancer. Comparative metabolomics showed that most metabolic differences were determined between the early stage (0–II) and the late stage (III and IV) among the 0–IV stages of esophageal cancer and between patients who received treatment and those who did not receive treatment. Glycine, serine, and threonine metabolism and glycine were identified as the potentially overlapped metabolic pathway and metabolite, respectively, in both disease progress and treatment effect. Glycine, fructose, ornithine, and threonine can be a potential array for the evaluation of disease prognosis and therapy in esophageal cancer. These results highlight the means of identifying previously unknown biomarkers related to esophageal cancer by a metabolomics approach. Frontiers Media S.A. 2022-09-13 /pmc/articles/PMC9513043/ /pubmed/36176418 http://dx.doi.org/10.3389/fonc.2022.938234 Text en Copyright © 2022 Yang, Wang, Ye, Jiang, Su, Peng, Li and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yang, Xiao-li
Wang, Peng
Ye, Hua
Jiang, Ming
Su, Yu-bin
Peng, Xuan-xian
Li, Hui
Zhang, Jian-ying
Untargeted serum metabolomics reveals potential biomarkers and metabolic pathways associated with esophageal cancer
title Untargeted serum metabolomics reveals potential biomarkers and metabolic pathways associated with esophageal cancer
title_full Untargeted serum metabolomics reveals potential biomarkers and metabolic pathways associated with esophageal cancer
title_fullStr Untargeted serum metabolomics reveals potential biomarkers and metabolic pathways associated with esophageal cancer
title_full_unstemmed Untargeted serum metabolomics reveals potential biomarkers and metabolic pathways associated with esophageal cancer
title_short Untargeted serum metabolomics reveals potential biomarkers and metabolic pathways associated with esophageal cancer
title_sort untargeted serum metabolomics reveals potential biomarkers and metabolic pathways associated with esophageal cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513043/
https://www.ncbi.nlm.nih.gov/pubmed/36176418
http://dx.doi.org/10.3389/fonc.2022.938234
work_keys_str_mv AT yangxiaoli untargetedserummetabolomicsrevealspotentialbiomarkersandmetabolicpathwaysassociatedwithesophagealcancer
AT wangpeng untargetedserummetabolomicsrevealspotentialbiomarkersandmetabolicpathwaysassociatedwithesophagealcancer
AT yehua untargetedserummetabolomicsrevealspotentialbiomarkersandmetabolicpathwaysassociatedwithesophagealcancer
AT jiangming untargetedserummetabolomicsrevealspotentialbiomarkersandmetabolicpathwaysassociatedwithesophagealcancer
AT suyubin untargetedserummetabolomicsrevealspotentialbiomarkersandmetabolicpathwaysassociatedwithesophagealcancer
AT pengxuanxian untargetedserummetabolomicsrevealspotentialbiomarkersandmetabolicpathwaysassociatedwithesophagealcancer
AT lihui untargetedserummetabolomicsrevealspotentialbiomarkersandmetabolicpathwaysassociatedwithesophagealcancer
AT zhangjianying untargetedserummetabolomicsrevealspotentialbiomarkersandmetabolicpathwaysassociatedwithesophagealcancer